Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Zinger Key Points
  • Important Biotech Catalysts For August 18, 2022 - EoD Summary
Loading...
Loading...
  • The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s KRYS Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted  Priority Review designation and assigned a target actin date of February 17, 2023. Krystal shares traded in a range of $72.05 to $74.88 on a day volume of 124.24 thousand shares, closed regular trading session at $74.41.
  • BioCryst Pharmaceuticals (NASDAQ: BCRX) announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Saudi Arabia. BioCryst shares traded in a range of $14.11 to $14.39 on a day volume of 2.11 million shares, closed regular trading session at $14.33.
  • Curis CRIS announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the TakeAim Lymphoma Phase 1/2 study of emavusertib after reviewing the comprehensive data package submitted by the company. Curis shares traded in a range of $1.23 to $1.77 on a day volume of 75.18 million shares, closed regular trading session at $1.26.
  • Aeglea BioTherapeutics AGLE announced that a Marketing Authorization Application (MAA) for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D) has been submitted to and successfully validated by the European Medicines Agency (EMA). Aeglea shares traded in a range of $0.49 to $0.54 on a day volume of 6.79 million shares, closed regular trading session at $0.5. The company shares are currently trading at $1.03, up 104  percent in the after-hours trading session.
  • Jazz Pharmaceuticals JAZZ announced it has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex® (cannabidiol), known as Epidyolex® in Europe, in children and adolescents with Epilepsy with Myoclonic-Atonic Seizures (EMAS). Jazz shares traded in a range of $155.23 to $158.36 on a day volume of 513.63 thousand shares, closed regular trading session at $156.55. The company shares are currently trading at $152.74, down 2.43 percent in the after-hours trading session.
  • Valneva VALN has initiated rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of its single-shot chikungunya vaccine candidate in persons aged 18 years and above. This BLA submission follows final pivotal Phase 3 data reported in March 2022. Valneva shares traded in a range of $19.6 to $21.02 on a day volume of 15.01 thousand shares, closed regular trading session at $20.58.
  • BridgeBio Pharma BBIO has dosed first patient in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by coenzyme A (CoA) deficiencies. BridgeBio shares traded in a range of $10.08 to $10.75 on a day volume of 1.74 million shares, closed regular trading session at $10.7.
  • 89bio ETNB has completed enrollment in ENLIVEN, the Phase 2b trial of pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH), expects to report topline data in the first quarter of 2023. 89bio shares traded in a range of $4.56 to $5.56 on a day volume of 871.79 thousand shares, closed regular trading session at $5.19. The company shares are currently trading at $5.37, up 3.47 percent in the after-hours trading session.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapFDAGeneralBiotech Catalysts - EOD Summary
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...